‘Time to Trust the Long-Term?' Analysts Maintain Buy on UnitedHealth Stock (UNH) Despite Price Target Cuts
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Nevertheless, both analysts maintain a Buy rating on UNH stock, citing confidence in long-term prospects.
Truist Lowers Target but Sees Stability Ahead
MacDonald lowered his price target on UnitedHealth to $345 from $360. The analyst expects Q2 results to show a mixed picture across the Healthcare sector, with some companies doing better than others depending on how they manage patient usage and costs.
Despite these short-term pressures, he is optimistic about the long-term outlook due to strong demand for healthcare services. Also, the Reconciliation Bill has made the rules and regulations clearer, which could help stabilize the company's business going forward.
Leerink Cuts Target but Projects Recovery by 2027
Leerink Partners' Mayo lowered the price target from $355 to $340, citing fading investor expectations as people wait for the company to update its 2025 financial guidance. He believes earnings in the $18–$19 per share range could ease concerns about shrinking margins.
On the positive side, the analyst sees this as the start of a long-term recovery. He expects profit margins to improve gradually over the next few years, with stronger growth likely starting in 2027, once the company finishes switching out of its current Medicare risk model.
Is UNH a Good Buy Right Now?
Turning to Wall Street, UNH stock has a Moderate Buy consensus rating based on 18 Buys, seven Holds, and one Sell assigned in the last three months. At $357.14, the average UnitedHealth stock price target implies a 21.75% upside potential.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Watch These UnitedHealth Price Levels as Stock Slumps on DOJ Probe Confirmation
UnitedHealth Group (UNH) shares tumbled Thursday after the health insurance giant confirmed that it's the subject of a Department of Justice investigation. The company said it's complying with formal criminal and civil requests from the DOJ, a development that follows months of reports that the agency is investigating UnitedHealth's billing practices in its Medicare Advantage program. Since setting their April high, UnitedHealth shares have lost more than half their value, with reports of federal scrutiny compounded by a downgraded profit forecast earlier this year and the departure of the company's CEO. Looking ahead, investors will be watching for updates on the DOJ probe and the company's financial performance when UnitedHealth reports earnings before the market opens next Tuesday. UnitedHealth shares fell nearly 5% on Thursday to $278.58, their lowest closing level since mid-May. The stock is the weakest performer in the Dow Jones Industrial Average in 2025. Below, we take a closer look at UnitedHealth's weekly chart and point out price levels that investors will likely be watching. Downtrend Resumes After Brief Consolidation After briefly consolidating in June, UnitedHealth shares have resumed their strong downtrend on increasing volume this month, a move that has coincided with the 50-week moving average (MA) crossing below the 200-day MA to form an ominous 'death cross.' While the relative strength index confirms bearish price momentum, it also flashes oversold conditions, potentially attracting bargain hunting in the stock. Let's locate two key support levels to watch on UnitedHealth's chart if the shares keep trending lower and also identify overhead areas worth monitoring during future recovery efforts in the stock. Key Support Levels to Watch The first lower level to watch sits around $250. This area may provide support near the May sell-off low, which closely aligns with a range of corresponding price action on the chart stretching back to early 2018. Selling below this key level opens the door for a retest of lower support near $215. Investors could look for long-term buying opportunities in this location close to a horizontal line that links a series of troughs on the chart from November 2017 to September 2019. Overhead Areas Worth Monitoring During recovery efforts in the stock, investors should initially monitor the $325 area. The price may encounter selling pressure in this region near last month's high, which lines up with a pullback to the 50-week MA in February 2021. Finally, a successful breakout above this area could fuel a move toward $368. Those who have accumulated UnitedHealth shares at lower levels may see this as a suitable location to lock in profits near the November 2020 and January 2021 peaks during an extended uptrend in the stock. The comments, opinions, and analyses expressed on Investopedia are for informational purposes only. Read our warranty and liability disclaimer for more info. As of the date this article was written, the author does not own any of the above securities. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Hill
4 hours ago
- The Hill
AARP endorses bill to prevent upcoding in Medicare Advantage
In a statement Thursday, AARP noted that upcoding is expected to increase care costs for Medicare Advantage enrollees by $40 billion this year. The No UPCODE Act was introduced by Sens. Bill Cassidy (R-La.) and Jeff Merkley (D-Ore.) earlier this year. The bill would disincentivize upcoding by developing a risk-adjustment model using two years of diagnostic data as opposed to one, limiting the use of unrelated medical conditions when estimating the cost of care, and bridging the gap between how patients on Medicare Advantage and traditional Medicare are assessed. In a letter to Cassidy and Merkley, AARP senior vice president for government affairs Bill Sweeney wrote, 'While many Medicare beneficiaries appreciate the flexibility and ease of use that MA provides, we are concerned that upcoding leads to both inflated payments to insurance plans and higher premiums for American seniors.' 'These resources would be better spent strengthening Medicare, such as by providing dental, hearing, and vision coverage,' Sweeney added. 'This bill addresses a problem both Republicans and Democrats have labeled as waste, fraud, and abuse. AARP agrees the No UPCODE Act protects seniors by preserving benefits and eliminating waste,' Cassidy said in a statement Thursday. 'When companies upcode, taxpayers foot the bill and patients get nothing. That's wrong.' While the Trump administration has railed against waste, fraud and abuse in Medicare and Medicaid, the vast majority of Medicare payments are made properly. As KFF found in its analysis of fiscal year 2024 payments, 94.4 percent of Medicare Advantage payments were made properly, with improper Medicare payments totaling $54.3 billion.
San Francisco Chronicle
8 hours ago
- San Francisco Chronicle
Bid by S.F.'s largest nursing home to restore 120 beds rejected by federal regulators
San Francisco's largest skilled nursing home, Laguna Honda, will not be able to reinstate 120 beds — which would have improved capacity for such care in the rapidly aging city — after federal regulators this month denied the hospital's attempt to gain approval for the expansion. The Centers for Medicare and Medicaid Services (CMS) turned down Laguna Honda's request to reinstate the beds, citing federal regulations that require nursing facilities certified after 2016 to limit residents to two per room. Reinstating the 120 beds would have meant Laguna Honda would have three residents in some of its rooms. CMS can make an exception to this rule by granting nursing homes a waiver allowing them more than two residents per room if they can show it meets residents' needs and will not harm their health and safety. Laguna Honda sought such a waiver in April, and was notified by CMS on July 7 that it was denied. In a letter to Laguna Honda leaders, CMS cited concerns about privacy, infection control and resident safety. It also cited hundreds of allegations of non-compliance, including allegations of abuse, neglect and resident rights violations since the hospital was recertified in 2023. Laguna Honda leaders said this was a 'gross mischaracterization' and that only six of the 276 allegations of non-compliance resulted in a cited deficiency, and that for each deficiency, the hospital completed a plan of correction. Compared to other large nursing facilities in California, Laguna Honda ranks in the middle for reported incidents and below the median for deficiencies, they said. 'We are very disappointed,' said Roland Pickens, director of San Francisco Health Network, which is owned and operated by the San Francisco Department of Public Health and includes Laguna Honda. Since 2010, Laguna Honda had 769 beds and housed three residents in some rooms, known as triples, because federal regulations allow that for nursing homes certified before 2016. But in 2022, the hospital lost its Medicare certification after state inspectors identified moderate to very serious deficiencies at the facility, including many residents testing positive for narcotics. The inspection was launched in 2021 after two residents overdosed but survived. During the process of regaining Medicare certification — a two-year saga that threatened to shut down the facility altogether — Laguna Honda had to decommission the triple rooms, reducing its skilled nursing beds from 769 to 649. It regained Medicare certification in 2024, which means it must comply with the regulation that limits residents to two per room for facilities certified after 2016. Laguna Honda then sought the waiver to add back the 120 beds, citing the critical need for skilled nursing care in San Francisco. The facility currently has about 550 residents. Laguna Honda leaders said they strongly disagree with CMS's decision but will not appeal or seek litigation challenging it. 'Pursuing legal action would be costly, time consuming and unlikely to yield a timely or favorable result — especially given CMS's broad discretion and the current political climate,' the public health department said. 'In the face of ongoing federal and state threats to Medicaid funding, local health departments like SFDPH must focus on protecting the broader system of care.'
